Afp4® Screening - Quadruple Marker Test (AFP, hCG, uE3, Inhibin A)
82105; 82677; 84702; 86336
Afp4 screens for fetal Down syndrome, trisomy 18 and open neural tube defects between 15 weeks / 0 days and 21 weeks / 6 days (15.0-21.9 weeks). Optimal time is between 16 and 18 weeks. Four biochemical markers, alphafetoprotein (AFP), human chorionic gonadotropin (hCG), unconjugated estriol (uE3) and dimeric Inhibin-A are analyzed in a maternal serum sample to provide risk assessments for Down syndrome, trisomy 18 and open neural tube defects in the second trimester.
Screening test for open neural tube defects (detects 80% open spina bifida, 90% anencephaly), Down syndrome (detects 75% to 80%), and trisomy 18 (detects 73%)
AFP Tetra; Alpha-Fetoprotein (AFP) Tetra Profile;
α-Fetoprotein, serum; dimeric inhibin A (DIA); human chorionic gonadotropin (hCG); unconjugated estriol (uE3)
Immunochemiluminometric assay (ICMA)
Whole blood; serum
Serum: 2-3 mL (unhemolyzed).
Whole Blood: 7 mL in SST or 10 ml in red-top tube; allow to clot; centrifuge (15 minutes at 1,000 g) to prevent hemolysis.
Serum: AFP tube
Whole Blood: Serum separator tube (SST) or red-top tube.
Avoid hemolysis. Send complete specimen in the original tube. Do not pour off.
Please Note: Ultrasound BPD (biparietal diameter) dating of pregnancy is preferred for optimal accuracy of risk calculations.
Causes for Rejection
Gross hemolysis; gross lipemia; quantity not sufficient for analysis
Maintain at room temperature